European Archives - Page 313 of 1389 - European Medical Journal

Is Gestational Diabetes Risk Reduced by High Protein Diet?

New research shows that animal and total protein intake could reduce the risk of gestational diabetes during pregnancy.

Ultra-Processed Foods and Their Impact on Allergies and Health

While food additives play a crucial role in food preservation and enhancement, their potential long-term effects on immune and metabolic health remain a growing concern.

Microwave Ablation for Renal Cell Carcinoma

Microwave ablation is an effective treatment modality for T1a and selected T1b renal cell carcinoma (RCC). Independent of the type of…

Illustration of a heart with a monitor

Could gene therapy transform heart failure treatment?

A gene therapy for heart failure with preserved ejection fraction (HFpEF) has shown promising early results.

Enzyme Spikes During Hepatitis D Treatment May Indicate Viral Suppression

A Phase 2 clinical trial finds that ALT flares are common in hepatitis D patients treated with pegylated interferon-alpha, but pose no safety risk, and may even signal better viral response.

AI in Medical Ethics: How ChatGPT Could Shape Medical Education

Discover how AI could revolutionize medical ethics training. Learn about LLMs’ potential in cultivating virtuous doctors.

One in Three Paediatric Adnexal Torsion Cases Face Delays

A new study finds delayed diagnosis of adnexal torsion affects nearly one-third of pediatric patients, with greater risk for those living farther from hospitals or in underserved areas.

Childhood BMI Linked to COPD Risk in Adulthood

Children with above-average BMI trajectories are at increased risk of developing chronic obstructive pulmonary disease later in life.

Seven Days of Antibiotics Sufficient for Gram-Negative Infections

New evidence suggests that a 7-day course of antibiotics is as effective as a 14-day regimen for most patients with Gram-negative bloodstream infections.

Boehringer Ingelheim's Christoph von der Goltz

Boehringer’s Christoph von der Goltz on setbacks and success in R&D

How can pharma navigate setbacks in drug development to deliver breakthroughs in R&D? Find out from Christoph von der Goltz, Boehringer.